Loading clinical trials...
Loading clinical trials...
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Conditions
Interventions
MAK683
Locations
16
United States
UCSF .
San Francisco, California, United States
UCLA Santa Monica Hematology Oncology
Santa Monica, California, United States
Uni Of TX MD Anderson Cancer Cntr Dept of Onc
Houston, Texas, United States
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
Shanghai, China
Start Date
October 3, 2016
Primary Completion Date
October 9, 2024
Completion Date
October 9, 2024
Last Updated
August 11, 2025
NCT05139017
NCT01804686
NCT07443514
NCT05755087
NCT04739813
NCT06785818
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions